Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event
LEUVEN, Belgium, March 22, 2017 /CNW/ -- TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that, CFO, Claudia D'Augusta, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on March 23, 2017. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
DATE: March 23rd, 2017
TIME: 09:00am EDT
This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
TiGenix: A compelling investment case with robust platform with solid phase III data:
- Positive pivotal phase III in complex perianal fistulas in Crohn's disease
- Results published in The Lancet (July 2016)
- EU approval decision expected in 2017
- Ex-US rights licensed to Takeda - best possible partner
- FDA's agreement on SPA obtained for pivotal phase III trial to start in 1H2017
- Pipeline with clinical-stage assets provides further upside
- Market cap ~EUR 180M (Euronext and Nasdaq: TIG) with strong, specialized, institutional shareholders. 18-24 months cash runway
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Our lead product candidate from the adipose-derived stem cell technology platform is Cx601, which is in registration with the European Medicines Agency for the treatment of complex perianal fistulas in Crohn's disease patients. Our adipose-derived stem cell product candidate Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. On July 4, 2016, TiGenix entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).
SOURCE TiGenix NV
For further information: For more information, Claudia D'Augusta, Chief Financial Officer, T: +34 91 804 92 64, email@example.com